Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Fuji
Argus Health
Express Scripts
Merck
Queensland Health
Healthtrust
Cantor Fitzgerald
Fish and Richardson
Federal Trade Commission

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,681,893

« Back to Dashboard

Summary for Patent: 4,681,893

Title: Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
Abstract:Certain trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-ones and the corresponding ring-opened acids derived therefrom which are potent inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG CoA reductase and are thus useful hypolipidemic or hypocholesterolemic agents. Pharmaceutical compositions containing such compounds, and a method of inhibiting the biosynthesis of cholesterol employing such pharmaceutical compositions are also disclosed.
Inventor(s): Roth; Bruce D. (Ann Arbor, MI)
Assignee: Warner-Lambert Company (Morris Plains, NJ)
Application Number:06/868,867
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

No matches for this query

International Patent Family for Patent: 4,681,893

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria60602► Subscribe
Australia601981► Subscribe
Australia7315987► Subscribe
Canada1268768► Subscribe
Germany19775019► Subscribe
Germany3767770► Subscribe
Denmark171588► Subscribe
Denmark271287► Subscribe
European Patent Office0247633► SubscribeSPC/GB97/011United Kingdom► Subscribe
European Patent Office0247633► SubscribeC970034Netherlands► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Merck
Harvard Business School
Colorcon
Cantor Fitzgerald
Citi
Queensland Health
Express Scripts
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot